Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1-f][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors

Citations Over TimeTop 17% of 2011 papers

Abstract

Chemical strategies to mitigate cytochrome P450-mediated bioactivation of novel 2,7-disubstituted pyrrolo[2,1-f][1,2,4]triazine ALK inhibitors are described along with synthesis and biological activity. Piperidine-derived analogues showing minimal microsomal reactive metabolite formation were discovered. Potent, selective, and metabolically stable ALK inhibitors from this class were identified, and an orally bioavailable compound (32) with antitumor efficacy in ALK-driven xenografts in mouse models was extensively characterized.

Related Papers

• → Identification and characterization of a bacterial cytochrome P450 for the metabolism of diclofenac(2009)39 cited
• → Cytochrome P450 2C8 and Flavin-containing Monooxygenases are Involved in the Metabolism of Tazarotenic Acid in Humans(2003)44 cited
• → Enzymes Involved in the Metabolism of the Carcinogen 2-Nitroanisole: Evidence for Its Oxidative Detoxication by Human Cytochromes P450(2004)19 cited
• Oxidation of 3-aminobenzanthrone, a human metabolite of carcinogenic environmental pollutant 3-nitrobenzanthrone, by cytochromes P450 - similarity between human and rat enzymes.(2009)
• Oxidation of 3-aminobenzanthrone, a human metabolite of carcinogenic environmental pollutant 3-nitrobenzanthrone, by cytochromes P450-similarity between human and rat enzymes(2009)